Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 1/2 Study of EBNK-001, an Allogeneic Natural Killer (NK) Cell Therapy Administered After Cyclophosphamide/Fludarabine Lymphodepletion With Low-Dose Interleukin-15, With or Without Pembrolizumab, in Participants With Advanced Solid Tumors

NCT07410676 is registered in ClinicalTrials.gov with Essen Biotech as lead sponsor.

NCT NCT07410676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07410676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 1/2 Study of EBNK-001, an Allogeneic Natural Killer (NK) Cell Therapy Administered After Cyclophosphamide/Fludarabine Lymphodepletion With Low-Dose Interleukin-15, With or Without Pembrolizumab, in Participants With Advanced Solid Tumors
Lead sponsor
Essen Biotech
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 1, 2026
Completion date
December 21, 2029
Enrollment
83 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, breast cancer (locally advanced or metastatic), cancer, colorectal cancer, esophageal cancer, glioblastoma, kidney cancer, leukaemia, liver cancer (primary and metastatic), lung cancer (diagnosis), melanoma (skin cancer), non-melanoma skin cancer, ovarian cancer, pancreatic cancer metastatic, sarcoma